IMNM

Over the past six months, Immunome's stock has been impacted by several events. In August 2026, the company reported Q2 2026 financial results, including a net loss of $73.1 million and $520.0 million in cash, cash equivalents, and marketable securities, expected to fund operations into 2028; the reported EPS of -$0.65 missed the consensus estimate of -$0.51. In September 2026, Immunome announced IND clearance for IM-1340, a potential first-in-class antibody-drug conjugate for solid tumors, which received mixed analyst views due to platform risk and a long path to positive cash flow; the company also presented at the H.C. Wainwright 28th Annual Global Investment Conference. In October 2026, Immunome reported inducement grants under Nasdaq Listing Rule 5635(c)(4); the stock price showed volatility, falling 26.26% over the last month but increasing 39.64% over the last year, and insider selling of $5,747,142.00 was reported in the past three months with no insider buying.